NCT02819856View on ClinicalTrials.gov

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

April 7, 2023

Study Completion Date

April 7, 2023

Conditions
Ototoxicity
Interventions
DRUG

Placebo

0 mg SPI-1005 bid po x 21d

DRUG

SPI-1005 Ebselen 200mg Capsule x1

200 mg SPI-1005 bid po x21d

DRUG

SPI-1005 Ebselen 200mg Capsule x2

400 mg SPI-1005 bid po x 21d

DRUG

SPI-1005 Ebselen 200mg Capsule x3

600 mg SPI-1005 bid po x 21d

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Sound Pharmaceuticals, Incorporated

INDUSTRY

NCT02819856 - SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity | Biotech Hunter | Biotech Hunter